Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Psychosis and Antipsychotic Drugs: Overview

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Clinically Meaningful Score Difference and Meaningful Score Regions in Positive and Negative Syndrome Scale Total Score from Post Hoc Analyses of a Phase 3 Pivotal Clinical Trial of Transdermal Asenapine in Patients with Schizophrenia.

Neuropsychiatric disease and treatment·2026

Same author

Relapse and its modifiers after antipsychotic discontinuation in first-episode non-affective psychosis: A systematic review and meta-analysis.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026

Same author

The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus.

The British journal of psychiatry : the journal of mental science·2026

Same author

Living with tardive dyskinesia: understanding the patient experience.

CNS spectrums·2026

Same author

Prescriber- and Patient-Level Characteristics Associated with Patient Adherence to Any Antipsychotics Among Patients with Schizophrenia in the United States.

Patient preference and adherence·2026

Same author

Recommendations for the Deprescribing of Psychotropic Medications: A Consensus Statement From the American Society of Clinical Psychopharmacology Task Force.

JAMA network open·2026

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Polypharmacy of schizophrenia.

Peter Dussias¹, Amir H Kalali, Leslie Citrome

¹Mr. Dussias is Executive Director, Strategic Analytics, Commercial Solutions, Quintiles, Inc., Parsippany, New Jersey.

Psychiatry (Edgmont (Pa. : Township))

|September 30, 2010

Summary

Physicians frequently use antipsychotic medications for schizophrenia treatment. Most regimens involve one medication (53%), with others adding antidepressants or mood stabilizers.

Keywords:

Schizophrenia antidepressants antipsychotics extrapyramidal symptoms mood stabilizers

More Related Videos

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Related Experiment Videos

Last Updated: Jun 8, 2026

Development of a Virtual Reality Assessment of Everyday Living Skills

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Area of Science:

Psychiatry
Pharmacology

Background:

Schizophrenia treatment involves complex medication regimens.
Understanding current prescribing practices is crucial for optimizing patient care.

Purpose of the Study:

To investigate the current clinical practice patterns for schizophrenia treatment.
To analyze the types and combinations of medications prescribed for schizophrenia.

Main Methods:

Data analysis of physician treatment choices for schizophrenia.
Categorization of medication regimens based on the number of products and drug classes.

Main Results:

One-product regimens are most common (53%), followed by two-product (29%) and three-or-more product regimens (18%).
Antipsychotic medications are central, present in 97% of regimens, and used alone in 56% of cases.
Adjunctive therapies include antidepressants (20%), mood stabilizers (15%), anti-anxiety drugs (7%), and extrapyramidal symptom treatments (6%).

Conclusions:

Current schizophrenia treatment heavily relies on antipsychotic monotherapy or combination therapy.
Adjunctive medications are frequently used to manage residual symptoms or comorbidities.